A subsidiary of Stemedica Cell Technologies Inc., Stemedica International S.A. was founded in 2008 as a global, biotechnology company that explores therapeutic applications of patented stem cells to treat degenerative diseases. In 2012 the Swiss Commission for Technology and Innovation (CTI) awarded Stemedica International and the Laboratory of Biomedical Optics at the École Polytechnique Fédérale de Lausanne (EPFL) a grant to develop practical applications of stem cell therapies and brain imaging for Alzheimer’s disease. The grant is designed to facilitate and accelerate transition from academic and pre-clinical research to the clinical phase and, ultimately, commercial use of stem cell therapies in treating Alzheimer’s disease.
Stemedica International has an exclusive rights to manufacture and apply Stemedica’s allogeneic, ischemia-tolerant mesenchymal (itMSC) and neural (itNSC) stem cell lines and stem cell factors to create therapies for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company also has Swissmedic licenses to import, export and distribute Stemedica’s cell lines worldwide for human use in approved clinical trials. Stemedica’s stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. Manufactured in compliance with cGMP, the technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union.
The company has headquarters in Lausanne, Switzerland, and a U.S. office in San Diego, California.